Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Ph+ CML-CP with Suboptimal Response to Imatinib
NCT01043874Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Major Molecular Response Rate at 12 months. Started Dec 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01043874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01043874.